Welcome to QIAGEN!
You can accept or revoke the cookies used on this website at any time with the selection below or by adjusting your cookie settings. For complete details about our cookies, see our Cookie Policy.
Multiplex PCR
Automated targeted PCR
Manual targeted PCR
RNA extraction
QIAsymphony DSP Virus/Pathogen Kit
Pour la purification automatisée des acides nucléiques viraux ou de l’ADN bactérien/pathogène de 1 à 96 échantillons
EZ1 DSP Virus Kit
pour la détection automatisée et simultanée des acides nucléiques viraux et de l’ADN bactérien provenant de 1à6 ou 1à14 échantillons biologiques humains à l’aide de l’EZ1 Advanced ou de Advanced XL
EZ1 Virus Mini Kit v2.0
For automated purification of viral nucleic acids from 1–6 or 1–14 samples per run
QIAamp 96 Virus QIAcube HT Kit
For automated high-throughput purification of viral RNA and DNA from a variety of samples
For QIAcube classic information please visit our resource hub.
Additional COVID-19 resources
QIAGEN solutions
-
QIAstat-Dx
The next generation of syndromic insights
Harness the full potential of multiplex syndromic testing and confidently provide clinical insights to patients with the highest level of versatility.
-
QIAGEN Digital Insights
Bioinformatics analysis of SARS-CoV-2 with QIAGEN Digital Insights
To support the efforts of labs sequencing the SARS-CoV-2 virus on the front lines of the COVID-19 pandemic, QIAGEN is offering free temporary licenses to researchers worldwide involved with COVID-19 research and response.
How can we support your lab?
Reach a specialist about SARS-CoV-2 resources.
*Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity and moderate complexity tests.
The QIAstat-Dx Respiratory SARS-CoV-2 Panel is intended for in vitro diagnostic use.
- Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity and moderate complexity tests.
- This test has not been FDA cleared or approved;
- This test has been authorized by FDA under an EUA for use by authorized laboratories;
- This test has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and
- This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
The NeuMoDx SARS-CoV-2 Assay is authorized under Emergency Use Authorization in the United States.
- This test has not been FDA cleared or approved but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories;
- This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and
- The emergency use of this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
The NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Assay is authorized under Emergency Use Authorization in the United States.
- This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories;
- This product has been authorized only for the detection and differentiation of nucleic acid from SARS-CoV-2, influenza A virus, influenza B virus, and/or Respiratory Syncytial Virus, not for any other viruses or pathogens; and
- The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
The artus SARS-CoV-2 Prep&Amp UM Kit has been validated but is pending Emergency Use Authorization by the FDA.